Medication info

Entence Injection

Prescription medicationSolution
Ingredient · strength
L-Alanine›0.92g / 100mLL-Arginine›0.79g / 100mLGlycine›0.72g / 100mLL-Histidine›0.2g / 100mLL-Isoleucine›0.33g / 100mLL-Leucine›0.48g / 100mLL-Lysine Acetate›0.61g / 100mLL-Methionine›0.28g / 100mLL-Phenylalanine›0.33g / 100mLL-Proline›0.73g / 100mLL-Serine›0.43g / 100mLTaurine›0.065g / 100mLL-Threonine›0.29g / 100mLL-Tryptophan›0.13g / 100mLL-Tyrosine›0.026g / 100mLL-Valine›0.41g / 100mLCalcium Chloride Hydrate›0.04g / 100mLSodium Glycerophosphate›0.23g / 100mLMagnesium Sulfate Heptahydrate›0.13g / 100mLPotassium Chloride›0.23g / 100mLSodium Acetate Hydrate›0.27g / 100mLZinc Sulfate Heptahydrate›0.001g / 100mLGlucose Monohydrate›9.3g / 100mLSoybean Oil›0.87g / 100mLTriglycerides Medium-Chain›0.87g / 100mLPurified Olive Oil›0.72g / 100mLPurified Fish Oil (High Dose Omega-3 Fatty Acids)›0.43g / 100mL
Manufacturer / importer
Fresenius Kabi Korea Ltd.
Appearance
This medication consists of a plastic container for infusion divided into three internal compartments, with an oxygen absorber placed in between. Each internal compartment contains an amino acid and electrolyte solution.
Packaging
506 milliliters/bag [×6 (A solution: 331 mL, B solution: 102 mL, C solution: 73 mL)], 1012 milliliters/bag [×4 (A solution: 662 mL, B solution: 204 mL, C solution: 146 mL)], 1518 milliliters/bag [×4 (A solution: 993 mL, B solution: 306 mL, C solution: 219 mL)], 2025 milliliters/bag [×4 (A solution: 1325 mL, B solution: 408 mL, C solution: 292 mL)]
Approval status
Active

MFDS item code 202203687 · Approved 2022.09.27 · Insurance code 650902141,650902142,650902143,650902144

Summary

Main use
Improvement of nutritional deficiencies through intravenous nutritional support
Who uses it
Adults · Children
Adult dosage
The dose and infusion rate should be determined according to the patient's ability to eliminate fat, metabolize nitrogen and glucose, and nutritional requirements. The dose should be individualized based on the patient's condition, body weight, nutritional and energy requirements, and additional oral/enteral intake. The nitrogen requirement for maintaining body protein depends on the patient's condition (e.g., nutritional status and catabolic stress or anabolism). Children 12 years of age and older and adults - Patients with normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg/day of amino acids (0.10-0.15 g/kg/day of nitrogen) - Patients experiencing moderate to severe metabolic stress, regardless of nutritional imbalance: 0.9-1.6 g/kg/day of amino acids (0.15-0.25 g/kg/day of nitrogen) - In very special cases (e.g., burns or marked anabolic states), the amount of nitrogen may be higher. Dose: A daily dose of 13-31 mL/kg of this medicine provides 0.85-2.0 g/kg of amino acids (0.14-0.32 g/kg of nitrogen) and 12-28 kcal/kg total energy (8-19 kcal/kg non-protein calories). This meets the requirements of most patients. In obese patients, the dose should be based on predicted ideal body weight. Infusion rate: The infusion rate should not exceed 1.5 mL/kg per hour (equivalent to 0.13 g/kg glucose, 0.10 g/kg amino acids, and 0.04 g/kg fat). Administration over 14-24 hours is recommended. Maximum daily dose: The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The maximum recommended daily dose is 31 mL/kg. The maximum recommended daily dose of 31 mL/kg provides 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories). Administration: Administer by intravenous infusion through a central vein.
Children's dosage
Children (2-11 years): Adjust the dose regularly according to requirements, up to 31 mL/kg of this medicine daily. The maximum recommended daily dose is 31 mL/kg, providing 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories). The maximum recommended infusion rate is 1.8 mL/kg per hour (equivalent to 0.12 g/kg amino acids, 0.15 g/kg glucose, and 0.05 g/kg fat). Except in special circumstances, administration at the maximum recommended infusion rate requires careful monitoring, and the infusion time should not exceed 17 hours. Administration over 12-24 hours is recommended.

Ingredients

Importer
Fresenius Kabi Korea Ltd.

Efficacy & effects

Improvement of nutritional deficiencies through intravenous nutritional support

  • Inability to provide nutrition orally or via gastrointestinal tract
  • insufficient nutrition supply
  • restricted nutrition supply.
View approved original text

This medication provides calories, amino acids, electrolytes, essential fatty acids, and omega-3 fatty acids to pediatric and adult patients over 2 years of age who are unable to intake nutrition orally or through the gastrointestinal tract. This helps improve the nutritional status of the patient and assists in recovery of health. It is mainly used for cases that require intravenous nutrition.

Dosage and Administration

Adult dosage

The dose and infusion rate should be determined according to the patient's ability to eliminate fat, metabolize nitrogen and glucose, and nutritional requirements. The dose should be individualized based on the patient's condition, body weight, nutritional and energy requirements, and additional oral/enteral intake. The nitrogen requirement for maintaining body protein depends on the patient's condition (e.g., nutritional status and catabolic stress or anabolism). Children 12 years of age and older and adults - Patients with normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg/day of amino acids (0.10-0.15 g/kg/day of nitrogen) - Patients experiencing moderate to severe metabolic stress, regardless of nutritional imbalance: 0.9-1.6 g/kg/day of amino acids (0.15-0.25 g/kg/day of nitrogen) - In very special cases (e.g., burns or marked anabolic states), the amount of nitrogen may be higher. Dose: A daily dose of 13-31 mL/kg of this medicine provides 0.85-2.0 g/kg of amino acids (0.14-0.32 g/kg of nitrogen) and 12-28 kcal/kg total energy (8-19 kcal/kg non-protein calories). This meets the requirements of most patients. In obese patients, the dose should be based on predicted ideal body weight. Infusion rate: The infusion rate should not exceed 1.5 mL/kg per hour (equivalent to 0.13 g/kg glucose, 0.10 g/kg amino acids, and 0.04 g/kg fat). Administration over 14-24 hours is recommended. Maximum daily dose: The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The maximum recommended daily dose is 31 mL/kg. The maximum recommended daily dose of 31 mL/kg provides 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories). Administration: Administer by intravenous infusion through a central vein.

Children's dosage

Children (2-11 years): Adjust the dose regularly according to requirements, up to 31 mL/kg of this medicine daily. The maximum recommended daily dose is 31 mL/kg, providing 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories). The maximum recommended infusion rate is 1.8 mL/kg per hour (equivalent to 0.12 g/kg amino acids, 0.15 g/kg glucose, and 0.05 g/kg fat). Except in special circumstances, administration at the maximum recommended infusion rate requires careful monitoring, and the infusion time should not exceed 17 hours. Administration over 12-24 hours is recommended.

Precautions

This drug must be used strictly according to a doctor's instructions, and if any symptoms of anaphylaxis reaction such as fever, chills, rash, or difficulty breathing occur during use, the administration must be stopped immediately. This drug should not be administered simultaneously with ceftriaxone via the same injection apparatus due to possible precipitation; therefore, the two drugs should not be given together, and the infusion line must be thoroughly washed before and after use. Caution is needed in premature or low-birth-weight infants as the lipid component of this medication may not be well eliminated from the body and could pose risks. This medication should not be administered to specific patient groups such as those with allergies to fish, eggs, soy, peanuts, severe liver, kidney, or blood coagulation disorders, those in acute shock, or uncontrolled hyperglycemia. Patients with conditions affecting fat metabolism such as renal failure, diabetes, or liver dysfunction require careful observation during administration. This medication may cause various adverse reactions involving the heart, respiratory system, gastrointestinal tract, and circulatory system; therefore, administration should be reduced or stopped if symptoms occur. During administration, regular monitoring of blood triglycerides, glucose, electrolytes, and liver enzyme levels is necessary to ensure no abnormalities, particularly in patients with hyperlipidemia, as there is a risk for fat overload syndrome. Due to a higher risk of infection with central venous infusion, strict aseptic techniques must be employed, and any possibility of deficiency due to increased excretion of trace elements during long-term administration must be considered. Safety has not been established for pregnant or lactating women; therefore, administration should be done cautiously and only when necessary. This drug is not recommended for children under 2 years of age as the amino acid composition is not suitable for their needs. The lipid components of this drug may affect certain clinical test results, so it is preferable to perform tests 5-6 hours after administration. In cases of overdose, the infusion rate should be slowed or stopped, and emergency measures should be taken if necessary; if hyperglycemia occurs, insulin administration or adjustment of the infusion rate may be necessary. Rapid and continuous infusion of this drug can be hazardous; therefore, whenever possible, a pump should be used for slow and steady infusion, and it should not be mixed with other medications.

Side effects

  • fever
  • chills
  • rash
  • difficulty breathing
  • tachycardia
  • loss of appetite
  • nausea
  • vomiting
  • increased plasma enzyme levels
  • hypotension
Show 33 more
  • hypertension
  • slight elevation of body temperature
  • dizziness
  • headache
  • anaphylaxis
  • skin rash
  • hives
  • flushing
  • warmth
  • coldness
  • cyanosis
  • pallor
  • sore throat
  • back pain
  • bone pain
  • chest pain
  • lower back pain
  • hyperlipidemia
  • fever
  • fatty infiltration
  • jaundice
  • hepatomegaly
  • splenomegaly
  • anemia
  • leukopenia
  • thrombocytopenia
  • coagulopathy
  • hemolysis
  • reticulocytosis
  • abnormal liver function test results
  • coma
  • sweating
  • hyperglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture intrusion. The storage temperature should be maintained at room temperature between 1°C and 25°C. This helps preserve the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

This medication consists of a plastic container for infusion divided into three internal compartments, with an oxygen absorber placed in between. Each internal compartment contains an amino acid and electrolyte solution.

Package unit

506 milliliters/bag [×6 (A solution: 331 mL, B solution: 102 mL, C solution: 73 mL)], 1012 milliliters/bag [×4 (A solution: 662 mL, B solution: 204 mL, C solution: 146 mL)], 1518 milliliters/bag [×4 (A solution: 993 mL, B solution: 306 mL, C solution: 219 mL)], 2025 milliliters/bag [×4 (A solution: 1325 mL, B solution: 408 mL, C solution: 292 mL)]

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.